Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has announced the voting results of its 41st Annual General Meeting (AGM), which was held on August 21, 2026. The meeting was conducted through video conferencing, and the resolutions proposed were approved with the requisite majority. The company has disclosed the voting results, including the number of shares held, votes polled, and percentage of votes in favor and against each resolution.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd held its 41st Annual General Meeting (AGM) on August 21, 2026, through video conferencing, with 38 shareholders present, including 6 from the promoter group. The meeting approved the audited financial statements for FY 2025-26 and re-appointed Mr. Natwarbhai Prajapati as a director and Mr. Aalap Prajapati as Managing Director & CEO.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has announced the re-appointment of Mr. Aalap Prajapati as the Managing Director & CEO for three consecutive years from 28 October 2026 to 27 October 2029.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has issued a corrigendum to correct an error in the tenure of re-appointment of its Managing Director & Chief Executive Officer, Mr. Aalap Prajapati, from 5 years to 3 years, commencing from 28 October 2026 to 27 October 2029.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has announced its unaudited standalone financial results for the first quarter ended 30 June 2026, with extracts published in newspapers Business Standard and Jai Hind. The results were approved by the Board of Directors on 7 August 2026 and published on 8 August 2026.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has announced its unaudited standalone financial results for the first quarter ended 30 June 2026, with the Board of Directors approving the results after a limited review by the statutory auditor.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has announced its unaudited standalone financial results for the first quarter ended 30 June 2026, with the Board of Directors approving the results subjected to a limited review by the statutory auditor.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has scheduled a board meeting on 7 August 2026 to consider and approve the unaudited standalone financial results for the first quarter ended 30 June 2026.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has announced its 41st Annual General Meeting to be held on August 21, 2026, through Video Conferencing and remote e-voting facility. The company has also disclosed its unaudited financial results for the quarter ended June 30, 2026, showing a revenue from operations of ₹4,170.47 crore and a net profit for the period of ₹274.57 crore.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd announced its 41st AGM will be held on 21st August, 2026. The company highlighted its 41-year history, built on relationships with healthcare professionals and patients. It showcased its 50 brands across 125 products and 10 therapeutic areas, with a focus on pediatric care and respiratory solutions. The company emphasized its strong market presence, consistent quality, and dependable outcomes.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has released its annual report for FY 2025-26, highlighting its 40-year journey of building relationships with healthcare professionals and creating a portfolio of 50 brands across 125 products and 10 therapeutic areas. The company's flagship brand, TYNOL, has maintained its market presence and growth potential, while ACOLATE has earned the trust of doctors and medical practitioners. The company aims to strengthen growth across its respiratory franchise in FY 2027.